Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
gptkb:physicist
long-acting beta-agonist |
| gptkbp:appointed_by |
inhalation
|
| gptkbp:approves |
gptkb:2011
gptkb:FDA |
| gptkbp:brand |
gptkb:Dulera
|
| gptkbp:clinical_trial |
maintenance therapy
preventive treatment asthma management COPD management |
| gptkbp:contains |
gptkb:formoterol
mometasone furoate |
| gptkbp:contraindication |
hypersensitivity to ingredients
|
| gptkbp:dosage_form |
inhalation aerosol
|
| gptkbp:formulation |
metered-dose inhaler
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dulera
|
| gptkbp:interacts_with |
MAO inhibitors
diuretics beta-blockers |
| gptkbp:is_used_for |
gptkb:asthma
chronic obstructive pulmonary disease |
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:pharmacokinetics |
excretion in urine
metabolism in liver systemic absorption |
| gptkbp:population |
adults
children over 12 |
| gptkbp:previous_name |
formoterol/mometasone
|
| gptkbp:price |
varies by pharmacy
insurance may cover |
| gptkbp:provides_information_on |
recommended for COPD management
recommended for moderate to severe asthma |
| gptkbp:release_region |
gptkb:legislation
gptkb:Australia gptkb:United_Kingdom gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:requires |
available online
|
| gptkbp:safety_features |
not for use in children under 12
may increase risk of pneumonia in COPD patients risk of asthma-related death |
| gptkbp:scholarships |
available for low-income patients
available through manufacturer rinse mouth after use not for acute asthma attacks |
| gptkbp:shelf_life |
3 years
|
| gptkbp:side_effect |
headache
nausea hoarseness thrush |
| gptkbp:storage |
room temperature
|
| gptkbp:bfsParent |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:bfsLayer |
3
|